The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Nature and Science of Sleep Pub Date : 2025-08-08 eCollection Date: 2025-01-01 DOI:10.2147/NSS.S498213
Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black
{"title":"The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis.","authors":"Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black","doi":"10.2147/NSS.S498213","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition.</p><p><strong>Patients and methods: </strong>Merative<sup>™</sup> MarketScan<sup>®</sup> Research Databases claims were analyzed (study period, 12/31/2013-2/29/2020). Eligible individuals were ≥18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2.</p><p><strong>Results: </strong>11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy.</p><p><strong>Conclusion: </strong>Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.</p>","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"1809-1823"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S498213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition.

Patients and methods: Merative MarketScan® Research Databases claims were analyzed (study period, 12/31/2013-2/29/2020). Eligible individuals were ≥18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2.

Results: 11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy.

Conclusion: Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.

Abstract Image

Abstract Image

Abstract Image

特发性嗜睡和发作性睡的临床和经济负担:一项基于美国索赔的分析。
目的:特发性嗜睡和发作性睡是两种相似但不同的睡眠障碍。本研究评估了两种疾病患者的临床和经济负担。患者和方法:分析了Merative™MarketScan®研究数据库的声明(研究期间,2013年12月31日- 2020年2月29日)。符合条件的个体年龄≥18岁,连续入组(入组前/入组后365天),并且有任何一种疾病的索赔。猝倒患者被排除在特发性嗜睡症队列之外。在研究期间,个人根据他们最早提出的条件进入队列。临床分类类别、选择条件、医疗资源利用(HCRU)和医疗费用在2年期间进行评估。汇总了有合并症的个体的百分比。每位患者每年平均(SD) HCRU和总全因医疗费用(PPPY)。HCRU和医疗费用PPPY是队列进入前/后365天的HCRU或医疗费用除以2。结果:11426例特发性嗜睡症患者和31214例嗜睡症患者被纳入研究。中位年龄分别为45岁和43岁;每个队列中大约65%是女性。所有类别的平均合并症数量分别为15.4(5.4)和14.6(5.7)。疾病定义不清(95.6%,94.4%)、神经系统疾病(83.8%,100.0%)和呼吸系统疾病(83.6%,79.1%)是最常见的广泛临床分类类别。两组患者均出现睡眠呼吸暂停(62.8%,52.1%)、高血压(45.7%,42.9%)、高脂血症(42.2%,38.4%)、疼痛(66.4%,66.0%)和情绪障碍(41.9%,43.3%)。对于特发性嗜睡或发作性睡患者,就诊≥1次的平均全因门诊就诊PPPY分别为28.2(40.1)和27.4(40.6)。特发性嗜睡或发作性睡症患者的平均全因医疗费用PPPY分别为11,134美元(22,674美元)和11591美元(25,956美元)。结论:发作性睡病和特发性嗜睡症患者的合并症会对医疗保健系统造成影响;在评估患有任何一种疾病的个人的整体健康状况时,可以考虑这些因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature and Science of Sleep
Nature and Science of Sleep Neuroscience-Behavioral Neuroscience
CiteScore
5.70
自引率
5.90%
发文量
245
审稿时长
16 weeks
期刊介绍: Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. Specific topics covered in the journal include: The functions of sleep in humans and other animals Physiological and neurophysiological changes with sleep The genetics of sleep and sleep differences The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness Sleep changes with development and with age Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause) The science and nature of dreams Sleep disorders Impact of sleep and sleep disorders on health, daytime function and quality of life Sleep problems secondary to clinical disorders Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health) The microbiome and sleep Chronotherapy Impact of circadian rhythms on sleep, physiology, cognition and health Mechanisms controlling circadian rhythms, centrally and peripherally Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms Epigenetic markers of sleep or circadian disruption.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信